White paper
The NDC-12 Cross-Industry Pilot: Key Findings & Insights From Phase 0
Understand the industry-wide impacts of the NDC-12 transition
Facing growing limitations in the availability of labeler codes within the current National Drug Code (NDC) framework, the FDA had released a proposed NDC-12 Rule in 2022 and published the finalized version on March 5th 2026.
Cencora and NNIT have partnered with a cross-industry panel of experts to develop a strategy to aid supply chain partners, regulatory bodies, and standards organizations in evolving the thinking towards the magnitude and complexity of the transformation from a 10-digit to a 12-digit NDC and deliver findings, ideas, and recommendations within key deliverables to the industry and regulators.
This white paper shows you
Key findings and early insights how NDC-12 affects life sciences and healthcare as a whole
An education and analysis of the final rule with background and details
Findings from a broad supply chain analysis and industry impact assessment
Fill out the form and discover how the NDC-12 transition can impact your organization, and what you should be doing to prepare:
